Understanding the Market | CIRC rose over 7% during trading as the company launched high-purity 13CO gas and urea products to support the comprehensive autonomy and controllability of the industrial chain

CIRC rose more than 7% during the session, and as of the time of writing, it is up 5.11%, trading at HKD 20.16, with a transaction volume of HKD 10.3578 million. On the news front, on October 31, the launch conference for the carbon isotope product release and the construction of the second phase of the stable isotope base project was successfully held in Tongcheng, Anhui. The high-abundance 13CO gas and urea products were officially released, marking a breakthrough for China in reducing its long-term reliance on imported 13CO gas for urea breath diagnostic materials. China has achieved comprehensive self-control of the entire industrial chain from key raw materials to end products in the field of medical stable isotope carbon, making the company a leading enterprise that fully masters the entire industrial chain of breath test products. According to public information, CIRC is a specialized company in the nuclear technology application sector of China National Nuclear Corporation, integrating nuclear energy development, production, sales, and services. Its main business includes nuclear medicine, radiation source products, nuclear medical equipment, and related technical services. The company has a complete industrial chain layout in the field of nuclear medicine, and as of December 31, 2024, it has established a network layout of 37 medical centers and has 7 R&D and production bases, making it a leading enterprise in China's nuclear medicine field